SEC Form 3 · accession 0001571049-15-005382
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per share, of Synageva | holding | — | — | — | 21,021,124 | I | Through direct, wholly owned subsidiary (see explanatory note) |
Table II — derivative securities
Remarks
This is a joint filing by Alexion Pharmaceuticals, Inc. ("Alexion") and Alexion Pharma LLC (as successor in interest to Pulsar Merger Sub Inc. ("Pulsar")), a direct, wholly owned subsidiary of Alexion. As previously announced, at midnight at the end of June 19, 2015, the exchange offer of Pulsar for all of the outstanding shares of Synageva BioPharma Corp. ("Synageva") expired. Alexion accepted for exchange all 21,021,124 shares of Synageva common stock validly tendered into the exchange offer and not properly withdrawn as of the expiration of the offer. Also as previously announced, on June 22, 2015, Alexion acquired all of the remaining shares of outstanding Synageva common stock through the merger of Pulsar with and into Synageva, with Synageva surviving the merger. Immediately following that merger, the corporation surviving that merger merged with and into Galaxy Merger Sub LLC, with Galaxy Merger Sub LLC surviving the merger and renamed "Alexion Pharma LLC."